Losartan/thioctic acid

Drug Profile

Losartan/thioctic acid

Alternative Names: Alpha lipoic acid/losartan; INV-144; Losartan/alpha lipoic acid; Thioctic acid/losartan

Latest Information Update: 07 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InVasc Therapeutics
  • Class Antihypertensives; Biphenyl compounds; Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic nephropathies

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-II for Diabetic nephropathies in USA (PO)
  • 01 Jul 2012 InVasc Therapeutics completes a phase I/II trial in Diabetic nephropathies in USA (NCT01398423)
  • 02 Apr 2012 InVasc Therapeutics completes enrolment in its phase II trial for Diabetic nephropathies in USA (NCT01398423)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top